Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?

Internal Medicine Journal

Volumn 43, Issue 5, 2013, Pages 599-603

  Nikpour, M ^a,b   Stevens, W ^b   Proudman, S M ^c   Buchbinder, R ^d,e   Prior, D ^a,b   Zochling, J ^f   Williams, T ^e   Gabbay, E ^g   Nandurkar, H ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d CABRINI HOSPITAL   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF TASMANIA   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Anticoagulation; Pulmonary arterial hypertension; Randomised controlled trial; Scleroderma; Systemic sclerosis

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; ENOXAPARIN; RIVAROXABAN; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG CONTRAINDICATION; EQUIPOISE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL HISTORY; OBSERVATIONAL STUDY; ORTHOPEDIC SURGERY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC SCLEROSIS; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HUMANS; HYPERTENSION, PULMONARY; SCLERODERMA, SYSTEMIC;

EID: 84877890328     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12111     Document Type: Article

References (35)

1. Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 2011; 63: 1182-1189.
2. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012; 51: 1017-1026.
3. Komocsi A, Vorobcsuk A, Faludi R, Pintér T, Lenkey Z, Költo G etal. The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2012; 51: 1027-1036.
4. Nikpour MPS, Roddy J, Byron J, Sahhar J, Nash P, Youssef P etal., for the Australian Scleroderma Interest Group. Mortality and cause of death in an Australian systemic sclerosis cohort. Ann Rheum Dis 2011; 70(Suppl. 3): 668.
5. Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE etal. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-1815.
6. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM etal. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 13S-24S.
7. McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford) 2009; 48 (Suppl 3): iii25-31.
8. Ngian GS, Stevens W, Prior D, Gabbay E, Roddy J, Tran A etal. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2012; 14: R213.
9. Berger G, Azzam ZS, Hoffman R, Yigla M. Coagulation and anticoagulation in pulmonary arterial hypertension. Isr Med Assoc J 2009; 11: 376-379.
10. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 2006; 130: 545-552.
11. Wagenvoort CA. Lung biopsy specimens in the evaluation of pulmonary vascular disease. Chest 1980; 77: 614-625.
12. Morrisroe KSW, Byron J, Thakkar V, Moore O, Proudman S, Nikpour M. Antiphospholipid antibodies in systemic sclerosis: prevalence and clinical correlations. Ann Rheum Dis 2012; 71(Suppl. 3): 402.
13. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-587.
14. Kawut SM, Horn EM, Berekashvili KK, Garofano RP, Goldsmith RL, Widlitz AC etal. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005; 95: 199-203.
15. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
16. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112: 714-721.
17. Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J 2006; 28: 999-1004.
18. Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Le T, Lee P etal. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. J Rheumatol 2012; 39: 276-285.
19. Ogata M, Ohe M, Shirato K, Takishima T. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. Jpn Circ J 1993; 57: 63-69.
20. Storstein O, Efskind L, Muller C, Rokseth R, Sander S. Primary pulmonary hypertension with emphasis on its etiology and treatment. Acta Med Scand 1966; 179: 197-212.
21. Roman A, Rodes-Cabau J, Lara B, Bravo C, Monforte V, Pallissa E etal. Clinico-hemodynamic study and treatment of 44 patients with primary pulmonary hypertension. Med Clin (Barc) 2002; 118: 761-766.
22. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917-1928.
23. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ etal. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S78-84.
24. Coghlan JG, Schreiber B. An update on the evaluation and management of pulmonary hypertension in scleroderma. Curr Rheumatol Rep 2012; 14: 1-10.
25. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA etal. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
26. Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Hawker GA, Feldman BM. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors. J Rheumatol 2011; 38: 462-469.
27. Marie I, Ducrotte P, Antonietti M, Herve S, Levesque H. Watermelon stomach in systemic sclerosis: its incidence and management. Aliment Pharmacol Ther 2008; 28: 412-421.
28. Ghrenassia EAJ, Derk CT, Airo P, Khanna D, Ingegnoli F, Rosato E etal. Watermelon stomach in SSc: a EUSTAR case control study. Rheumatology (Oxford) 2012; 51: S.3.1.
29. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011; 31: 326-343.
30. del Zoppo GJ, Eliasziw M. New options in anticoagulation for atrial fibrillation. N Engl J Med 2011; 365: 952-953.
31. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010; 115: 15-20.
32. Hylek EM. Therapeutic potential of oral factor Xa inhibitors. N Engl J Med 2010; 363: 2559-2561.
33. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-2498.
34. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
35. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M etal. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.